Related Experiment Videos
Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer
Cancer Chemotherapy and Pharmacology
|January 1, 1985
Summary
Medroxyprogesterone acetate IP administered intraperitoneally for advanced cancer yields higher plasma drug levels. Oral and intramuscular routes show significantly lower absorption rates, with oral absorption averaging 5.7% and intramuscular averaging 2.5%.
Area of Science:
- Oncology
- Pharmacokinetics
- Drug Delivery
Background:
- Advanced cancer with peritoneal metastases and ascitic effusion presents challenges for effective drug delivery.
- Medroxyprogesterone acetate is utilized in cancer treatment, but its absorption varies significantly by administration route.
Purpose of the Study:
- To compare the pharmacokinetic profiles of medroxyprogesterone acetate IP, PO, and IM administration routes.
- To quantify the absorption rates of medroxyprogesterone acetate via oral and intramuscular routes in cancer patients.
Main Methods:
- Pharmacokinetic analysis comparing plasma drug concentrations and AUCs across different administration routes.
- Calculation of absorbed dose percentages for oral (PO) and intramuscular (IM) medroxyprogesterone acetate.
Main Results:
- Intraperitoneal (IP) administration of medroxyprogesterone acetate IP resulted in substantially higher plasma drug levels compared to PO and IM routes.
- Oral absorption of medroxyprogesterone acetate ranged from 0.2% to 17.4% (mean 5.7%) in 40 patients.
- Intramuscular absorption of medroxyprogesterone acetate ranged from 0.7% to 7.7% (mean 2.5%) per injection site in 30 patients.
Conclusions:
- Intraperitoneal administration offers superior bioavailability of medroxyprogesterone acetate IP in patients with advanced cancer and peritoneal involvement.
- Oral and intramuscular routes demonstrate limited and variable absorption, suggesting suboptimal delivery for this patient population.